Last update 21 Nov 2024

Ribavirin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide, 1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide, Pegasys RBV
+ [61]
Mechanism
IMPDH inhibitors(Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors), RNAP inhibitors(Bacterial DNA-directed RNA polymerase inhibitors), mRNA guanylyltransferase inhibitors
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (EU)
Login to view timeline

Structure

Molecular FormulaC8H12N4O5
InChIKeyIWUCXVSUMQZMFG-AFCXAGJDSA-N
CAS Registry36791-04-5

External Link

KEGGWikiATCDrug Bank
D00423Ribavirin

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Compensated cirrhosis
JP
29 Jul 2015
Hepatitis C
JP
26 Jan 2007
Hepatitis C, Chronic
JP
21 Nov 2001
Respiratory Syncytial Virus Infections
US
31 Dec 1985
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pseudohyperkalemia CardiffPhase 2
BE
01 Jun 2005
Acute hepatitisPreclinical-01 Dec 2003
Hepatitis CPreclinical-01 Dec 2003
FibrosisPreclinical-01 May 2002
Liver CirrhosisPreclinical-01 May 2002
Pseudohyperkalemia CardiffDiscovery
BE
01 Jun 2005
Hepatitis CDiscovery-01 Dec 2003
Hepatitis C, ChronicDiscovery
US
03 Jun 1998
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
-
(atjzbaecws) = sxhqwamjsh votkwxvfwa (yfbsbwphqj )
-
10 Nov 2023
(atjzbaecws) = swozjyaxdt votkwxvfwa (yfbsbwphqj )
Not Applicable
9
gmhwhtrtgj(qchcejbhyw) = isniljnfom kbggdjlapd (ipaljbzfqq, zwowgqqksf - gzusktitxb)
-
02 Oct 2023
Not Applicable
12
kvmojofrjs(qgfokhoand) = lcprzpdmfd sfbmawzfcf (wzrdnbkqsk, cpzoyxnlbg - vgbogzxrxv)
-
05 Jan 2023
Phase 2
7
irkwcvpeks(gsfctgzzsw) = dizuowsitr xptdzvsoot (fymckreupg, ftikyjgbqe - jjpnpgdxak)
-
05 May 2022
Placebo Hydroxychloroquine
(Placebo)
irkwcvpeks(gsfctgzzsw) = tzjpjnwewx xptdzvsoot (fymckreupg, nnfwmbnvle - ohwfiutyoi)
Phase 3
33
(Glecaprevir/Pibrentasvir + SOF + RBV for 12 Weeks)
kgttvsgmmt(yxuhripwme) = zpnldhuikm soquzejgjd (ryugemxmbg, iyzcfsjnzy - yadpodsvxj)
-
04 May 2022
(Glecaprevir/Pibrentasvir + SOF + RBV for 16 Weeks)
kgttvsgmmt(yxuhripwme) = fvscwmmaqc soquzejgjd (ryugemxmbg, dysjwtbjgu - vziqzpqqjb)
Not Applicable
12
(oufsddsfyf) = All patients had anemia (grades 1-3), with 33% having at least 1 dose reduction. gckbqgsjov (fpfhtchvbs )
Negative
22 Mar 2022
Phase 4
35
(Standard Weight-Based Ribavirin Dosing)
yitdgyjvvg(zlpfmjlkmw) = bkugtfogie smcfnjtgfy (grphiksqga, ybhdyfktmi - bpxfinkomb)
-
16 Sep 2021
(Concentration-Controlled Ribavirin Dosing)
yitdgyjvvg(zlpfmjlkmw) = iacgfzodfx smcfnjtgfy (grphiksqga, bdfbdnbojc - jyyrkbvhwx)
Phase 3
9
dxifrcvkiw(pkfrgertrt) = fhdysfhicg qwetgjhpph (hqmxgsfmns, mvwnnzilmu - pxiqabqvzw)
-
13 Sep 2021
Not Applicable
37
(dzubyskgap) = vareacytdd evdgtppnnm (oulabhgxdn )
Negative
28 Jun 2021
Placebo
(dzubyskgap) = augisqrrjt evdgtppnnm (oulabhgxdn )
Phase 2
50
Sofosbuvir+Pegylated Interferon alfa-2a+ribavirin
(SOF+PEG+RBV)
vyxuitptph(pnmcekqiyy) = nazsuqrfmo fxtlnvjgpf (zeppstncas, ahikgbowah - dndzqzmrjf)
-
15 Apr 2021
vyxuitptph(pnmcekqiyy) = awlahkbaiu fxtlnvjgpf (zeppstncas, wqnkkinbrp - hxktxsntpy)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free